Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL862402 | 0.94 | MEN1 (0.41) | KMT2AMEN1KDM4EALDH1A1GAA | |
| SCHEMBL862408 | 0.88 | BCHE (0.38) | KMT2AMEN1KDM4EALDH1A1ALOX15 | |
| SCHEMBL841840 | 0.87 | BCHE (0.38) | KMT2AMEN1KDM4EALDH1A1ALOX15 | |
| SCHEMBL14338918 | 0.87 | KMT2A (0.34) | KMT2AMEN1KDM4EALDH1A1GAA | |
| SCHEMBL842177 | 0.86 | ALDH1A1 (0.41) | KMT2AMEN1KDM4EALDH1A1GAA | |
| SCHEMBL5738697 | 0.84 | LMNA (0.42) | KDM4EALDH1A1TDP1GPR35ALOX15 | |
| SCHEMBL20634265 | 0.83 | MCL1 (0.54) | KMT2AMEN1KDM4EALDH1A1LMNA | |
| SCHEMBL5748574 | 0.83 | MCL1 (0.41) | KDM4EALDH1A1TDP1GPR35ALOX15 | |
| SCHEMBL10387678 | 0.82 | LMNA (0.49) | KDM4EALDH1A1TDP1GPR35ALOX15 | |
| SCHEMBL25483550 | 0.81 | MCL1 (0.50) | KMT2AMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694672-B1 | NOVEL CHELATING AGENTS AND HIGHLY LUMINESCENT AND STABLE CHELATES AND THEIR USE | WALLAC OY (FI) | 2012-06-20 | — | — | EP | disclosed |
| US-8143057-B2 | Chelating agents and highly luminescent and stable chelates and their use | WALLAC OY (FI) | 2012-03-27 | — | — | US | disclosed |
| US-8143057-B2 | Chelating agents and highly luminescent and stable chelates and their use | WALLAC OY (FI) | 2012-03-27 | — | — | US | disclosed |
| US-8071626-B2 | Chromophoric moiety comprises trialkoxyphenylpyridyl groups; biochemical conjugation; for solid phase synthesis of oligonucleotides and oligopeptides; magnetic resonance imaging; positron emission tomography | WALLAC OY (FI) | 2011-12-06 | — | — | US | disclosed |
| US-8071626-B2 | Chromophoric moiety comprises trialkoxyphenylpyridyl groups; biochemical conjugation; for solid phase synthesis of oligonucleotides and oligopeptides; magnetic resonance imaging; positron emission tomography | WALLAC OY (FI) | 2011-12-06 | — | — | US | disclosed |
| US-8071626-B2 | Chromophoric moiety comprises trialkoxyphenylpyridyl groups; biochemical conjugation; for solid phase synthesis of oligonucleotides and oligopeptides; magnetic resonance imaging; positron emission tomography | WALLAC OY (FI) | 2011-12-06 | — | — | US | disclosed |
| US-20100036102-A1 | NOVEL CHELATING AGENTS AND HIGHLY LUMINESCENT AND STABLE CHELATES AND THEIR USE | WALLAC OY (FI) | 2010-02-11 | — | — | US | disclosed |
| US-20100036102-A1 | NOVEL CHELATING AGENTS AND HIGHLY LUMINESCENT AND STABLE CHELATES AND THEIR USE | WALLAC OY (FI) | 2010-02-11 | — | — | US | disclosed |
| US-7625930-B2 | Chelating agents and highly luminescent and stable chelates and their use | WALLOC OY (FI) | 2009-12-01 | — | — | US | disclosed |
| US-7625930-B2 | Chelating agents and highly luminescent and stable chelates and their use | WALLOC OY (FI) | 2009-12-01 | — | — | US | disclosed |
| US-7625930-B2 | Chelating agents and highly luminescent and stable chelates and their use | WALLOC OY (FI) | 2009-12-01 | — | — | US | disclosed |
| US-20080167443-A1 | Novel chelating agents and highly luminescent and stable chelates and their use | WALLAC OY (FI) | 2008-07-10 | — | — | US | disclosed |
| US-20080167443-A1 | Novel chelating agents and highly luminescent and stable chelates and their use | WALLAC OY (FI) | 2008-07-10 | — | — | US | disclosed |
| US-20080167443-A1 | Novel chelating agents and highly luminescent and stable chelates and their use | WALLAC OY (FI) | 2008-07-10 | — | — | US | disclosed |
| EP-1694672-A1 | NOVEL CHELATING AGENTS AND HIGHLY LUMINESCENT AND STABLE CHELATES AND THEIR USE | WALLAC OY (FI) | 2006-08-30 | — | — | EP | disclosed |
| US-20050181393-A1 | Novel chelating agents and highly luminescent and stable chelates and their use | WALLAC OY (FI) | 2005-08-18 | — | — | US | disclosed |
| WO-2005058877-A1 | NOVEL CHELATING AGENTS AND HIGHLY LUMINESCENT AND STABLE CHELATES AND THEIR USE | WALLAC OY (FI) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036102-A1 | NOVEL CHELATING AGENTS AND HIGHLY LUMINESCENT AND STABLE CHELATES AND THEIR USE | CLTA, CLTC, FOLH1 | KMT2A 1390/4885MEN1 3630/4885KDM4E 3409/4885 |
| US-20080167443-A1 | Novel chelating agents and highly luminescent and stable chelates and their use | CLTA, CLTC, FOLH1 | KMT2A 1390/4885MEN1 3630/4885KDM4E 3409/4885 |
| US-20050181393-A1 | Novel chelating agents and highly luminescent and stable chelates and their use | CLTA, CLTC, FOLH1 | KMT2A 1390/4885MEN1 3630/4885KDM4E 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.